Leerink Partners Initiates Tekmira Pharmaceuticals At Outperform

by Monica Gerson, Benzinga Staff Writer
August 18, 2014 8:00 AM | 12 seconds read |
Analysts at Leerink Partners initiated coverage on Tekmira Pharmaceuticals TKMR with a Outperform rating. The target price for Tekmira Pharmaceuticals is set to $25. Tekmira Pharmaceuticals' shares gained 6.08% to $19.18 in pre-market trading.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: InitiationAnalyst RatingsLeerink Partners
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!